Earendil Labs announced a $787 million private financing to expand an AI-driven drug discovery platform that the company says has produced more than 40 programs. The funding positions Earendil to advance multiple preclinical candidates and to prepare for a potential public listing. Investors cited the firm’s high-throughput computational approach and early pipeline breadth as drivers of the large round. The round signals continued investor appetite for AI-native biotechs that promise to compress discovery timelines. Earendil’s platform reportedly integrates generative models and experimental feedback to progress multiple modalities in parallel. For readers: “foundation models” and other large AI systems are being repurposed to predict molecule properties and prioritize candidates across many targets. The company’s cash will accelerate IND-enabling studies and broaden discovery efforts, but execution risks remain around preclinical-to-clinic translation and regulatory scrutiny of AI-designed assets. The raise will also set valuation and comparables for other AI-biotech entrants heading toward late-stage private rounds or IPOs.